29 August 2017 - - The cell line development service market is expected to grow at double digit CAGR to reach USD 1,214.7m by 2025, according to a report from Dublin-based Research and Markets.

The cell line development services global market was estimated region wise, by type of cell lines expression systems, by cell types and by application.

This report also contains cost analysis for various cell line development services. Key developments such as collaborations, acquisitions, new launches, partnerships and expansions were reported and analysed.

Increasing demand for biologics and biosimilars, growing incidence rate of oncology and immunological disorder and growth in research activities related to the diseases are driving the market.

Technological improvements in development, manufacturing, screening technologies and assays are giving immense growth opportunity for the market. However, complexities in development of stable cell lines and high risk of contamination due to complex purification methods are restraining the market.

Furthermore, stringent and complex regulations and high cost and technical requirement to adhere with accreditations such as GMP are posing threat to the industry.

Cell lines are essential for a wide range of applications including gene function studies, drug discovery assays, the production of biotherapeutics and diagnostics.

The application for cell lines includes research, bioproduction and diagnostics. Among research, cell lines are used for studying disease, screening, cell-based assays are used during discovery phase and preclinical development.

Cell lines are used to produce a wide range of biotherapeutics including vaccine, recombinant proteins that include peptides, cytokines, hormones and clotting factors, enzymes and monoclonal antibodies.

Key players in this market include Abzena Plc, Boehringer Ingelheim, Catalent Inc., Charles River Laboratories, Cook Pharmica, Crown Biosciences, Fujifilm Holdings Corp., Genscript Biotech Corp., Horizon Discovery Group, Plc, Jhl Biotech Inc., Lonza Group, Merck Kgaa, Patheon N.V., Rentschler Biotechnologie Gmbh, Sartorius Stedim Biotech S.A, Selexis Sa, Shanghai Medicilon, Shangpharma Corp. /Shanghai Chempartner, Syngene International and Wuxi Apptec.